Gilead Says Indian Co. Is Infringing HIV Drug Patents

Law360, New York (August 12, 2016, 7:12 PM EDT) -- Gilead Sciences Inc. and Emory University on Thursday accused Indian drugmaker Hetero Drugs Ltd. in New Jersey federal court of infringing four patents for the HIV treatment Truvada by applying to make a generic with the U.S. Food and Drug Administration.

The patent owners and licensees said Hetero and its U.S. arm, Hetero USA Inc., submitted an abbreviated new drug application to the FDA before the valid patents had expired, proving the company has “committed an act of infringement.”

Gilead holds the new drug application for Truvada, which contains 200 milligrams of emtricitabine and 300 mg of tenofovir disoproxil fumarate. The...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS